Attardi Barbara J, Engbring Jean A, Gropp David, Hild Sheri Ann
Division of Reproductive Endocrinology and Toxicology, BIOQUAL Inc, 9600 Medical Center Dr, Rockville, MD 20850, USA.
J Androl. 2011 Sep-Oct;32(5):530-40. doi: 10.2164/jandrol.110.011817. Epub 2010 Dec 16.
Dimethandrolone undecanoate (DMAU: 7α,11β-dimethyl-19-nortestosterone 17β-undecanoate) is a potent orally active androgen with progestational activity that is in development for therapeutic uses in men. We hypothesized that because of its dual activity, DMAU might have potential as a single-agent oral hormonal contraceptive. To test this possibility, adult male rabbits (5/group) of proven fertility were treated orally with vehicle or DMAU at 1.0, 2.5, 5.0, or 10.0 mg/kg/d for 12 or 13 weeks. Semen and blood samples were collected every other week through week 30. Sperm were decreased (P < .05) in semen samples from DMAU-treated rabbits at 2.5 and 5.0 mg/kg/d at weeks 12, 14, 16, 18, and 20 compared to week 0 (prior to treatment). The percentage of forward progressive motile sperm in those rabbits that still had measurable sperm was also reduced by DMAU treatment at 2.5 mg/kg/d at weeks 14, 16, 18, and 20 and at 5.0 mg/kg/d at week 18 (P < .05). At 1.0 mg/kg/d only 1 rabbit had reduced sperm numbers and motility. A mating trial was performed at week 15. The number of bred males that were fertile was 4 of 4 in the vehicle-treated group and 4 of 5, 0 of 4, and 2 of 5 in the 1.0, 2.5, and 5.0 mg/kg/d DMAU treatment groups. By week 22, sperm numbers and forward progressive motility increased, and they returned to pretreatment levels in all DMAU-treated rabbits by week 30. All bred males were fertile at week 31. Serum levels of testosterone, follicle-stimulating hormone (FSH), and luteinizing hormone (LH) were significantly suppressed in DMAU (1.0, 2.5, or 5.0 mg/kg/d)-treated rabbits during the 12-week dosing interval, but were comparable to pretreatment levels after cessation of dosing. These data indicate that DMAU suppressed the hypothalamic-pituitary-gonadal axis, resulting in severe oligospermia in the majority of rabbits in the 2.5 and 5.0 mg/kg/d dosing groups. Infertility was observed when sperm numbers decreased to about 10% of pretreatment levels. In rabbits dosed with DMAU at 10.0 mg/kg/d, no effect on sperm numbers or motility was observed by week 12. Dosing continued for another week, and the rabbits underwent a gross necropsy on week 13 with removal of testes and epididymides for histology and preparation of testicular cytosol. Serum testosterone, FSH, and LH levels were considerably suppressed in these rabbits as in the lower-dose groups. The lack of oligospermia in the 10.0 mg/kg group as well as in the 2 fertile males in the 5.0 mg/kg group may have been due to high intratesticular levels of 7α,11β-dimethyl-19-nortestosterone, the active metabolite of DMAU. Hence, as observed previously for testosterone, DMAU has a biphasic effect on spermatogenesis. Collectively, these data indicate that DMAU has the potential to be an orally active single-agent male hormonal contraceptive at an appropriate dose level and should be tested for contraceptive efficacy in nonhuman primates.
十一酸二甲双雄醇酮(DMAU:7α,11β - 二甲基 - 19 - 去甲睾酮17β - 十一酸酯)是一种具有孕激素活性的强效口服活性雄激素,正处于用于男性治疗用途的研发阶段。我们推测,由于其双重活性,DMAU可能有潜力作为一种单药口服激素避孕药。为了验证这种可能性,将已证实具有生育能力的成年雄性兔子(每组5只)口服给予赋形剂或1.0、2.5、5.0或10.0mg/kg/d的DMAU,持续12或13周。每隔一周采集精液和血液样本,直至第30周。与第0周(治疗前)相比,在第12、14、16、18和20周时,给予2.5和5.0mg/kg/d DMAU治疗的兔子精液样本中的精子数量减少(P < 0.05)。在那些仍有可测量精子的兔子中,在第14、16、18和20周给予2.5mg/kg/d以及在第18周给予5.0mg/kg/d的DMAU治疗也降低了向前运动精子的百分比(P < 0.05)。在1.0mg/kg/d时,只有1只兔子的精子数量和活力降低。在第15周进行了交配试验。赋形剂治疗组中可育的配种雄性数量为4/4,而在1.0、2.5和5.0mg/kg/d DMAU治疗组中分别为5/4、4/0和5/2。到第22周时,精子数量和向前运动能力增加,到第30周时,所有接受DMAU治疗的兔子的精子数量和活力恢复到治疗前水平。在第31周时,所有配种雄性均具有生育能力。在12周的给药间隔期间,给予DMAU(1.0、2.5或5.0mg/kg/d)治疗的兔子血清睾酮、促卵泡激素(FSH)和促黄体生成素(LH)水平显著受到抑制,但在停药后与治疗前水平相当。这些数据表明,DMAU抑制下丘脑-垂体-性腺轴,导致2.5和5.0mg/kg/d给药组中的大多数兔子出现严重少精子症。当精子数量降至治疗前水平的约10%时观察到不育。在给予10.0mg/kg/d DMAU的兔子中,到第12周时未观察到对精子数量或活力的影响。给药持续另一周,在第13周对兔子进行大体尸检,取出睾丸和附睾用于组织学检查和制备睾丸胞质溶胶。与低剂量组一样,这些兔子的血清睾酮、FSH和LH水平也受到显著抑制。10.0mg/kg组以及5.0mg/kg组中的2只可育雄性缺乏少精子症可能是由于睾丸内7α,11β - 二甲基 - 19 - 去甲睾酮(DMAU的活性代谢产物)水平较高。因此,正如先前对睾酮的观察一样,DMAU对精子发生有双相作用。总体而言,这些数据表明,DMAU在适当剂量水平下有潜力成为一种口服活性单药男性激素避孕药,应在非人类灵长类动物中测试其避孕效果。